株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

迷走神経刺激装置:パイプライン分析

Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016

発行 GlobalData 商品コード 345364
出版日 ページ情報 英文 96 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
迷走神経刺激装置:パイプライン分析 Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016
出版日: 2016年11月01日 ページ情報: 英文 96 Pages
概要

当レポートでは、世界各国の企業・医療機関などで開発が進められている迷走神経刺激装置のパイプライン製品情報について分析しており、治験と製品開発の進行状況、段階別・セグメント別・国 (地域) 別の動向、企業と製品の詳細情報、最近の製品開発および業界の動向などの情報を盛り込んでいます。

第1章 目次

第2章 イントロダクション

  • 迷走神経刺激装置の概要

第3章 開発中の製品

  • 迷走神経刺激装置 - 開発段階別のパイプライン製品
  • 迷走神経刺激装置 - 国 (地域) 別のパイプライン製品
  • 迷走神経刺激装置 - 規制別のパイプライン製品
  • 迷走神経刺激装置 - 認証時期別 (推定) のパイプライン製品
  • 迷走神経刺激装置 - 現在進行中の治験

第4章 迷走神経刺激装置 - 開発中のパイプライン製品:企業別

  • 迷走神経刺激装置企業 - 開発段階別のパイプライン製品
  • 迷走神経刺激装置 - 開発段階別のパイプライン製品

第5章 迷走神経刺激装置企業と製品の概要

  • BioControl Medical
  • Boston Scientific Corporation
  • CerboMed GmbH
  • Cerebral RX Ltd.
  • Children's Hospital Boston
  • Cyberonics, Inc.
  • DuoCure Ltd.
  • ElectroCore, LLC
  • Medical University of South Carolina
  • MicroTransponder Inc.
  • Neurostream Technologies G.P.
  • Setpoint Medical Corporation
  • Sorin S.p.A.
  • Trifectas Medical Corp.

第6章 迷走神経刺激装置 - 最近の動向

第7章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0250EPD

GlobalData's Medical Devices sector report, "Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016" provides an overview of Vagus Nerve Stimulators currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vagus Nerve Stimulators pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Vagus Nerve Stimulators under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Vagus Nerve Stimulators and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Vagus Nerve Stimulators under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Vagus Nerve Stimulators Overview

3. Products under Development

  • 3.1. Vagus Nerve Stimulators - Pipeline Products by Stage of Development
  • 3.2. Vagus Nerve Stimulators - Pipeline Products by Territory
  • 3.3. Vagus Nerve Stimulators - Pipeline Products by Regulatory Path
  • 3.4. Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date
  • 3.5. Vagus Nerve Stimulators - Ongoing Clinical Trials

4. Vagus Nerve Stimulators - Pipeline Products under Development by Companies

  • 4.1. Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development
  • 4.2. Vagus Nerve Stimulators - Pipeline Products by Stage of Development

5. Vagus Nerve Stimulators Companies and Product Overview

  • 5.1. BioControl Medical Company Overview
    • 5.1.1. BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Boston Scientific Corporation Company Overview
    • 5.2.1. Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. CerboMed GmbH Company Overview
    • 5.3.1. CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Cerebral RX Ltd. Company Overview
    • 5.4.1. Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Cyberonics, Inc. Company Overview
    • 5.5.1. Cyberonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. DuoCure Ltd. Company Overview
    • 5.6.1. DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. ElectroCore, LLC Company Overview
    • 5.7.1. ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. LivaNova PLC Company Overview
    • 5.8.1. LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Medical University of South Carolina Company Overview
    • 5.9.1. Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. MicroTransponder Inc. Company Overview
    • 5.10.1. MicroTransponder Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Neurostream Technologies G.P. (Inactive) Company Overview
    • 5.11.1. Neurostream Technologies G.P. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Purdue University Company Overview
    • 5.12.1. Purdue University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. Setpoint Medical Corp Company Overview
    • 5.13.1. Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. Trifectas Medical Corp. Company Overview
    • 5.14.1. Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview

6. Vagus Nerve Stimulators- Recent Developments

  • 6.1. Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016
  • 6.2. Oct 19, 2016: SetPoint Medical Presents Positive Clinical Results in Crohn's Disease
  • 6.3. Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results
  • 6.4. Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
  • 6.5. Sep 29, 2016: LivaNova Announces Half-Year Financial Report
  • 6.6. Aug 03, 2016: LivaNova Reports Second Quarter 2016 Results
  • 6.7. Aug 01, 2016: LivaNova Names Chief Operating Officer
  • 6.8. Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016
  • 6.9. Jul 26, 2016: Use of electroCore's therapy reduces frequency of migraine attacks in chronic patients
  • 6.10. Jul 21, 2016: Reorganization of electroCore management team as Frank Amato becomes CEO and founder JP Errico becomes Chief Science and Strategy Officer
  • 6.11. Jul 20, 2016: St. Jude Medical Reports Second Quarter 2016 Results
  • 6.12. Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors
  • 6.13. Jul 06, 2016: LivaNova Sets Operating Model and Supporting Organization
  • 6.14. Jul 05, 2016: Breakthrough First-in-Human Study Shows Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, Inhibits Cytokine Production
  • 6.15. Jun 29, 2016: ElectroCore Raises USD1.5 Million in Venture Financing
  • 6.16. Jun 24, 2016: Five presentations at AHS meeting provide new insights into non-invasive vagus nerve stimulation's mode of action
  • 6.17. Jun 15, 2016: ElectroCore's non-invasive vagus nerve stimulation (nVNS) demonstrates efficacy in preventing cluster headache and menstrual migraine
  • 6.18. Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
  • 6.19. Jun 06, 2016: Seven presentations on electroCore's treatment for cluster headache and migraine will feature at American Headache Society science meeting
  • 6.20. May 31, 2016: Ergoresearch announce the nomination of an Executive Vice-President
  • 6.21. May 27, 2016: Ergoresearch Reports its Results for the Quarter Ended March 31, 2016
  • 6.22. May 17, 2016: GammaCore is both effective and cost effective for the treatment of cluster headache
  • 6.23. May 04, 2016: LivaNova Reports First Quarter 2016 Results
  • 6.24. Apr 19, 2016: Studies presented at the American Academy of Neurology meeting confirm nVNS is stimulating the vagus nerve non-invasively and that nVNS can be effective in preventing menstrual migraine
  • 6.25. Apr 01, 2016: NICE provides positive guidance on electroCore's gammaCore treatment for the prevention and acute treatment of migraine and cluster headache
  • 6.26. Feb 29, 2016: Second Quarter Results ended December 31, 2015 - Ergoresearch reports its results for the quarter ended December 31, 2015
  • 6.27. Feb 24, 2016: LivaNova Reports 2015 Annual and Fourth Quarter Financial Results
  • 6.28. Jan 19, 2016: University of Bonn study shows that non-invasive vagus nerve stimulation (nVNS) device reduces number of migraine attacks and their intensity
  • 6.29. Jan 06, 2016: ElectroCore Appoints Desitin to Launch gammaCore for the Treatment of Primary Headache across Germany
  • 6.30. Jan 05, 2016: LivaNova Provides Update on FDA Warning Letter
  • 6.31. Dec 23, 2015: Mittel Plans to Sell 6% Interest in LivaNova
  • 6.32. Nov 19, 2015: Checkpoint Surgical Raises USD7.5 Million in Venture Financing
  • 6.33. Nov 12, 2015: LivaNova Provides Business Update

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development
  • Table 2: Vagus Nerve Stimulators - Pipeline Products by Territory
  • Table 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path
  • Table 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date
  • Table 5: Vagus Nerve Stimulators - Ongoing Clinical Trials
  • Table 6: Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development
  • Table 7: Vagus Nerve Stimulators - Pipeline Products by Stage of Development
  • Table 8: BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: CardioFit System - Product Status
  • Table 10: CardioFit System - Product Description
  • Table 11: Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: AMT System - Product Status
  • Table 13: AMT System - Product Description
  • Table 14: Vagal Nerve Stimulator - Product Status
  • Table 15: Vagal Nerve Stimulator - Product Description
  • Table 16: Boston Scientific Corporation - Ongoing Clinical Trials Overview
  • Table 17: Vagal Nerve Stimulator - Neural Cardiac Therapy for Heart Failure Study
  • Table 18: CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 19: t-VNS - Dementia - Product Status
  • Table 20: t-VNS - Dementia - Product Description
  • Table 21: Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 22: FitNes System - Alzheimer's Disease - Product Status
  • Table 23: FitNes System - Alzheimer's Disease - Product Description
  • Table 24: Cyberonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 25: Aspire NP - Product Status
  • Table 26: Aspire NP - Product Description
  • Table 27: Centro Generator - Product Status
  • Table 28: Centro Generator - Product Description
  • Table 29: Griffin - Pulse Generator - Product Status
  • Table 30: Griffin - Pulse Generator - Product Description
  • Table 31: Nerve Wrap - Product Status
  • Table 32: Nerve Wrap - Product Description
  • Table 33: PhoenixRF SR - Product Status
  • Table 34: PhoenixRF SR - Product Description
  • Table 35: DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: Intraluminal Implantable Device - Product Status
  • Table 37: Intraluminal Implantable Device - Product Description
  • Table 38: ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: GammaCore - Cluster Headache - Product Status
  • Table 40: GammaCore - Cluster Headache - Product Description
  • Table 41: GammaCore - Medication Overuse Headache - Product Status
  • Table 42: GammaCore - Medication Overuse Headache - Product Description
  • Table 43: GammaCore - Migraine - Product Status
  • Table 44: GammaCore - Migraine - Product Description
  • Table 45: ElectroCore, LLC - Ongoing Clinical Trials Overview
  • Table 46: GammaCore - Migraine - A Prospective, Multi-center, Randomized, Double-blind, Sham-controlled Study of the gammaCore-S Non-invasive Vagus Nerve Stimulation Device (NVNS), for the Acute Treatment of Migraine
  • Table 47: GammaCore - Cluster Headache - A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of the gammaCore, a Non-invasive Neurostimulator Device, for the Prevention of Episodic Migraine
  • Table 48: GammaCore - Cluster Headache - Non-Invasive Vagus Nerve Stimulation Treatment for Headache Using GammaCore
  • Table 49: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 50: CentroSR Generator - Product Status
  • Table 51: CentroSR Generator - Product Description
  • Table 52: Equilia - Product Status
  • Table 53: Equilia - Product Description
  • Table 54: VITARIA System - Chronic Heart Failure - Product Status
  • Table 55: VITARIA System - Chronic Heart Failure - Product Description
  • Table 56: LivaNova PLC - Ongoing Clinical Trials Overview
  • Table 57: VITARIA System - Chronic Heart Failure - VITARIA Registry Study
  • Table 58: Equilia - Vagal Nerve Stimulation: Safe-guarding Heart Failure Patients (VANGUARD)
  • Table 59: Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview
  • Table 60: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Status
  • Table 61: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Description
  • Table 62: MicroTransponder Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 63: SAINT System - Anxiety Disorders - Product Status
  • Table 64: SAINT System - Anxiety Disorders - Product Description
  • Table 65: SAINT System - Tinnitus - Product Status
  • Table 66: SAINT System - Tinnitus - Product Description
  • Table 67: Serenity System - Tinnitus - Product Status
  • Table 68: Serenity System - Tinnitus - Product Description
  • Table 69: Vivistim Device - Product Status
  • Table 70: Vivistim Device - Product Description
  • Table 71: MicroTransponder Inc. - Ongoing Clinical Trials Overview
  • Table 72: Vivistim Device - A Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function after Stroke (MicroTransponder's Vivistim System) - Study MT-St-02 - Stroke
  • Table 73: Neurostream Technologies G.P. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 74: Neuromodulation Device - Epilepsy - Product Status
  • Table 75: Neuromodulation Device - Epilepsy - Product Description
  • Table 76: Neuromodulation Device - Sleep Apnea - Product Status
  • Table 77: Neuromodulation Device - Sleep Apnea - Product Description
  • Table 78: Purdue University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 79: Bionode Device - Product Status
  • Table 80: Bionode Device - Product Description
  • Table 81: Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 82: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Status
  • Table 83: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Description
  • Table 84: SetPoint Immune System Regulator - Crohn's Disease - Product Status
  • Table 85: SetPoint Immune System Regulator - Crohn's Disease - Product Description
  • Table 86: Setpoint Medical Corp - Ongoing Clinical Trials Overview
  • Table 87: SetPoint Immune System Regulator - Crohn's Disease - Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-inflammatory Pathway Using a Vagal Nerve Stimulation Device in Patients with Active Refractory Crohn's Disease
  • Table 88: Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 89: Neurostimulation Device - Stroke Recovery - Product Status
  • Table 90: Neurostimulation Device - Stroke Recovery - Product Description
  • Table 91: Glossary

List of Figures

  • Figure 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development
  • Figure 2: Vagus Nerve Stimulators - Pipeline Products by Territory
  • Figure 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path
  • Figure 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date
  • Figure 5: Vagus Nerve Stimulators - Ongoing Clinical Trials
Back to Top